Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.56−0.04 (-6.21%)

Close on Nov 13, 2026Market cap $155.12MP/E –Yield –

Humacyte operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Humacyte's operating cash flow for the twelve months ending Sep 30, 2026 was -$88.26M. For fiscal 2025 it was -$105.04M. The highest annual figure on record is -$55.57M in fiscal 2020.

Annual operating cash flow

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$105.04M	–
FY2024	Dec 31, 2024	-$98.12M	–
FY2023	Dec 31, 2023	-$73.31M	–
FY2022	Dec 31, 2022	-$71.13M	–
FY2021	Dec 31, 2021	-$81.19M	–
FY2020	Dec 31, 2020	-$55.57M	–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$14.97M	–
Q2 FY2026	Jun 30, 2026	-$22.06M	–
Q1 FY2026	Mar 31, 2026	-$25.10M	–
Q4 FY2025	Dec 31, 2025	-$26.12M	–
Q3 FY2025	Sep 30, 2025	-$23.90M	–
Q2 FY2025	Jun 30, 2025	-$26.41M	–
Q1 FY2025	Mar 31, 2025	-$28.60M	–
Q4 FY2024	Dec 31, 2024	-$26.58M	–
Q3 FY2024	Sep 30, 2024	-$22.91M	–
Q2 FY2024	Jun 30, 2024	-$21.29M	–
Q1 FY2024	Mar 31, 2024	-$27.35M	–
Q4 FY2023	Dec 31, 2023	-$19.05M	–
Q3 FY2023	Sep 30, 2023	-$13.01M	–
Q2 FY2023	Jun 30, 2023	-$22.60M	–
Q1 FY2023	Mar 31, 2023	-$18.64M	–
Q4 FY2022	Dec 31, 2022	-$18.96M	–
Q3 FY2022	Sep 30, 2022	-$16.80M	–
Q2 FY2022	Jun 30, 2022	-$16.57M	–
Q1 FY2022	Mar 31, 2022	-$18.80M	–
Q4 FY2021	Dec 31, 2021	-$21.45M	–
Q3 FY2021	Sep 30, 2021	-$30.52M	–
Q2 FY2021	Jun 30, 2021	-$14.68M	–
Q1 FY2021	Mar 31, 2021	-$14.54M	–
Q4 FY2020	Dec 31, 2020	-$15.20M	–
Q3 FY2020	Sep 30, 2020	-$18.05K	–